Price to Sales (P/S)
since 2005
Calculation
Bristol-Myers Squibb Co., P/S, long-term trends, calculation
| P/S | = | Share price1, 2, 3 | ÷ | Sales per share1 | Sales per share1 | = | Revenues1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 12, 2025 | 2.36 | = | 56.15 | ÷ | 23.80 | 23.80 | = | 48,300 | ÷ | 2,029,312,023 | |
| Feb 13, 2024 | 2.19 | = | 48.71 | ÷ | 22.26 | 22.26 | = | 45,006 | ÷ | 2,022,193,411 | |
| Feb 14, 2023 | 3.29 | = | 72.25 | ÷ | 21.99 | 21.99 | = | 46,159 | ÷ | 2,098,775,978 | |
| Feb 9, 2022 | 3.16 | = | 67.14 | ÷ | 21.28 | 21.28 | = | 46,385 | ÷ | 2,179,712,820 | |
| Feb 10, 2021 | 3.16 | = | 60.00 | ÷ | 18.98 | 18.98 | = | 42,518 | ÷ | 2,240,475,153 | |
| Feb 24, 2020 | 5.52 | = | 63.97 | ÷ | 11.58 | 11.58 | = | 26,145 | ÷ | 2,257,510,796 | |
| Feb 25, 2019 | 3.67 | = | 50.65 | ÷ | 13.82 | 13.82 | = | 22,561 | ÷ | 1,632,675,877 | |
| Feb 13, 2018 | 5.02 | = | 63.87 | ÷ | 12.73 | 12.73 | = | 20,776 | ÷ | 1,632,582,502 | |
| Feb 21, 2017 | 4.72 | = | 54.78 | ÷ | 11.61 | 11.61 | = | 19,427 | ÷ | 1,672,715,340 | |
| Feb 12, 2016 | 6.07 | = | 60.20 | ÷ | 9.92 | 9.92 | = | 16,560 | ÷ | 1,669,459,090 | |
| Feb 13, 2015 | 6.28 | = | 60.04 | ÷ | 9.55 | 9.55 | = | 15,879 | ÷ | 1,662,118,446 | |
| Feb 14, 2014 | 5.48 | = | 54.37 | ÷ | 9.93 | 9.93 | = | 16,385 | ÷ | 1,650,232,566 | |
| Feb 15, 2013 | 3.40 | = | 36.58 | ÷ | 10.76 | 10.76 | = | 17,621 | ÷ | 1,637,354,662 | |
| Feb 17, 2012 | 2.63 | = | 33.12 | ÷ | 12.58 | 12.58 | = | 21,244 | ÷ | 1,688,107,071 | |
| Feb 18, 2011 | 2.23 | = | 25.49 | ÷ | 11.44 | 11.44 | = | 19,484 | ÷ | 1,702,427,438 | |
| Feb 19, 2010 | 2.27 | = | 24.95 | ÷ | 10.97 | 10.97 | = | 18,808 | ÷ | 1,714,140,539 | |
| Feb 20, 2009 | 1.96 | = | 20.37 | ÷ | 10.41 | 10.41 | = | 20,597 | ÷ | 1,979,509,306 | |
| Feb 22, 2008 | 2.30 | = | 22.53 | ÷ | 9.77 | 9.77 | = | 19,348 | ÷ | 1,979,387,706 | |
| Feb 26, 2007 | 3.07 | = | 27.19 | ÷ | 8.87 | 8.87 | = | 17,914 | ÷ | 2,019,481,440 | |
| Mar 14, 2006 | 2.34 | = | 22.91 | ÷ | 9.80 | 9.80 | = | 19,207 | ÷ | 1,959,073,035 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Bristol-Myers Squibb Co. Annual Report.
The analysis of the financial trends for the given periods reveals several key insights into the company's performance and market valuation metrics.
- Share Price
- The share price experienced fluctuations over the observed years. Starting at $22.91 in 2006, it demonstrated a generally upward trend with some volatility. Notable peaks occurred around 2014 to 2016, reaching above $60, and again in 2022 and 2023 with values over $67 and $72 respectively. A decline is observed in the latest years, dropping to $48.71 in 2024 before recovering slightly to $56.15 in 2025. Overall, the share price more than doubled during the period despite intermittent declines.
- Sales per Share
- Sales per share showed a steady increase from $9.8 in 2006 to $23.8 by 2025. There was consistent growth with minor fluctuations, including some periods of decline such as from 2014 to 2016. The most significant increase appears after 2019, where sales per share rose sharply from $11.58 to nearly $24 by 2025, indicating strong revenue growth on a per-share basis in the recent years.
- Price-to-Sales (P/S) Ratio
- The P/S ratio exhibits considerable variability, reflecting changing investor sentiment and valuation multiples over time. Initially, in 2006, the ratio stood at 2.34, peaking at 6.28 in 2015, which corresponds to the period when the share price was at its highest relative to sales. Following 2015, the P/S ratio decreased and stabilized around 3.0 in the later years, dropping as low as 2.19 in 2024 before a slight recovery in 2025. This decline suggests that despite rising sales per share, the market valuation became more conservative relative to sales, particularly in the most recent years.
In summary, the data indicate increasing sales efficiency per share over the long term, supported by a general upward trend in share price with periods of volatility. Meanwhile, valuation multiples reflected by the P/S ratio peaked mid-period and have moderated more recently, suggesting adjustments in market expectations relative to sales growth.
Comparison to Competitors
Bristol-Myers Squibb Co., P/S, long-term trends, comparison to competitors
| Bristol-Myers Squibb Co. | AbbVie Inc. | Amgen Inc. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 12, 2025 | 2.36 | 6.04 | 4.88 | 6.23 | 18.25 | 4.98 | 4.26 | 3.60 | 2.32 | 5.52 | 4.73 | 10.78 |
| Feb 13, 2024 | 2.19 | 5.72 | 5.78 | 7.76 | 20.77 | 3.40 | 4.43 | 5.43 | 2.61 | 7.84 | 4.99 | 11.16 |
| Feb 14, 2023 | 3.29 | 4.61 | 5.17 | 5.79 | 10.96 | 3.86 | 4.34 | 4.71 | 2.35 | 7.01 | 4.73 | 8.56 |
| Feb 9, 2022 | 3.16 | 4.53 | 5.10 | 6.37 | 8.01 | 2.85 | 4.66 | 3.96 | 3.15 | 4.20 | 5.39 | 8.21 |
| Feb 10, 2021 | 3.16 | 4.05 | 5.64 | 7.01 | 8.06 | 3.24 | 5.15 | 3.93 | 4.42 | 6.24 | 5.52 | 8.82 |
| Feb 24, 2020 | 5.52 | 4.22 | 6.03 | 6.29 | 6.03 | 4.00 | 4.79 | 4.33 | 3.66 | 5.34 | 4.83 | 14.95 |
| Feb 25, 2019 | 3.67 | 3.58 | 5.22 | 3.97 | 5.15 | 3.84 | 4.45 | 4.92 | 4.49 | 6.62 | 4.24 | 15.54 |
| Feb 13, 2018 | 5.02 | 6.67 | 5.82 | 3.70 | 3.71 | 4.10 | 4.56 | 3.68 | 4.05 | 5.92 | 4.01 | 16.42 |
| Feb 21, 2017 | 4.72 | 3.84 | 5.65 | 3.48 | 4.18 | 3.08 | 4.62 | 4.54 | 3.84 | 7.86 | 3.37 | 12.51 |
| Feb 12, 2016 | 6.07 | 3.83 | 5.28 | 2.91 | 4.02 | 3.80 | 4.13 | 3.56 | 3.76 | 9.38 | 3.05 | 20.38 |
| Feb 13, 2015 | 6.28 | 4.90 | 6.13 | 3.09 | 4.03 | 6.36 | 3.77 | 3.93 | 4.24 | 14.62 | 3.06 | 47.41 |
| Feb 14, 2014 | 5.48 | 4.31 | 5.22 | 2.78 | 2.81 | 11.95 | 3.63 | 3.78 | 3.97 | 15.52 | 3.74 | 16.53 |
| Feb 15, 2013 | 3.40 | 3.30 | 4.09 | 2.32 | 2.71 | 6.95 | 3.17 | 2.73 | 3.34 | 11.66 | 2.12 | 6.60 |
| Feb 17, 2012 | 2.63 | — | 3.52 | 2.28 | 1.87 | 4.22 | 2.75 | 2.43 | 2.37 | 20.90 | 1.77 | 5.61 |
| Feb 18, 2011 | 2.23 | — | 3.32 | 2.48 | 1.73 | 4.19 | 2.65 | 2.18 | 2.27 | 7.38 | 2.00 | 56.82 |
| Feb 19, 2010 | 2.27 | — | 3.88 | 2.16 | 1.82 | 6.64 | 2.82 | 4.23 | 2.83 | 5.74 | 1.98 | 80.12 |
| Feb 20, 2009 | 1.96 | — | 3.44 | 1.30 | 1.66 | 8.03 | 2.37 | 2.14 | 1.72 | 5.17 | 1.44 | 28.70 |
| Feb 22, 2008 | 2.30 | — | 3.46 | 2.16 | 3.05 | 10.90 | 2.95 | 4.04 | 3.11 | 11.94 | 2.40 | 12.17 |
| Feb 26, 2007 | 3.07 | — | 5.41 | 2.30 | 3.80 | 12.67 | 3.53 | 4.23 | 3.67 | 19.70 | 5.05 | 17.58 |
| Mar 14, 2006 | 2.34 | — | 7.24 | 2.40 | 4.31 | 15.36 | 3.49 | 3.50 | 3.77 | 14.06 | 2.15 | 26.93 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Bristol-Myers Squibb Co., P/S, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Bristol-Myers Squibb Co. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 12, 2025 | 2.36 | 5.55 |
| Feb 13, 2024 | 2.19 | 5.89 |
| Feb 14, 2023 | 3.29 | 4.56 |
| Feb 9, 2022 | 3.16 | 4.50 |
| Feb 10, 2021 | 3.16 | 4.90 |
| Feb 24, 2020 | 5.52 | 4.88 |
| Feb 25, 2019 | 3.67 | 4.54 |
| Feb 13, 2018 | 5.02 | 4.60 |
| Feb 21, 2017 | 4.72 | 4.29 |
| Feb 12, 2016 | 6.07 | 4.10 |
| Feb 13, 2015 | 6.28 | 4.54 |
| Feb 14, 2014 | 5.48 | 4.30 |
| Feb 15, 2013 | 3.40 | 3.25 |
| Feb 17, 2012 | 2.63 | 2.58 |
| Feb 18, 2011 | 2.23 | 2.44 |
| Feb 19, 2010 | 2.27 | 3.00 |
| Feb 20, 2009 | 1.96 | 2.22 |
| Feb 22, 2008 | 2.30 | 3.19 |
| Feb 26, 2007 | 3.07 | 3.88 |
| Mar 14, 2006 | 2.34 | 3.84 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Bristol-Myers Squibb Co., P/S, long-term trends, comparison to industry (health care)
| Bristol-Myers Squibb Co. | Health Care | |
|---|---|---|
| Feb 12, 2025 | 2.36 | 2.61 |
| Feb 13, 2024 | 2.19 | 2.72 |
| Feb 14, 2023 | 3.29 | 39,755.53 |
| Feb 9, 2022 | 3.16 | 2.65 |
| Feb 10, 2021 | 3.16 | 2.59 |
| Feb 24, 2020 | 5.52 | 2.51 |
| Feb 25, 2019 | 3.67 | 2.51 |
| Feb 13, 2018 | 5.02 | 2.49 |
| Feb 21, 2017 | 4.72 | 2.29 |
| Feb 12, 2016 | 6.07 | 2.30 |
| Feb 13, 2015 | 6.28 | 2.62 |
| Feb 14, 2014 | 5.48 | 2.38 |
| Feb 15, 2013 | 3.40 | 1.87 |
| Feb 17, 2012 | 2.63 | 1.66 |
| Feb 18, 2011 | 2.23 | 1.57 |
| Feb 19, 2010 | 2.27 | 1.77 |
| Feb 20, 2009 | 1.96 | 1.47 |
| Feb 22, 2008 | 2.30 | 2.14 |
| Feb 26, 2007 | 3.07 | 2.60 |
| Mar 14, 2006 | 2.34 | 2.90 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).